ArticlePharmaceutical research2026
A Sulfonamide-Based Compound DRZ-V Enhances Wound Repair via Macrophage-Mediated Responses Associated with TIRAP-NF-κB Signaling.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMacrophage polarization is a critical determinant of wound healing outcomes, regulating the transition from inflammation to tissue repair. Failure to shift from a pro-inflammatory M1 phenotype to a reparative M2 phenotype contributes to chronic inflammation and delayed wound healing. Although the sulfonamide-based small molecule DRZ-V has shown anti-inflammatory properties, its role in macrophage functional reprogramming during wound repair has not been explored. This study investigated whether DRZ-V promotes macrophage phenotypic transition and enhances wound healing through modulation of TIRAP-mediated NF-κB signaling.
methodsWound healing activity was evaluated using a full-thickness excisional wound model in mice. Macrophage polarization and cytokine expression were analyzed in RAW 264.7 macrophages by quantitative real-time PCR. The influence of macrophage-conditioned media on fibroblast migration was assessed using an in vitro scratch assay. TIRAP phosphorylation and NF-κB p65 activation were examined by immunoblotting and immunofluorescence analyses.
resultsDRZ-V significantly accelerated wound closure in vivo. In macrophages, DRZ-V suppressed LPS-induced inflammatory responses by reducing pro-inflammatory cytokine expression while enhancing M2-associated markers, including Arg1, FIZZ1, and Ym1. DRZ-V also restored the expression of reparative mediators such as TGF-β and PDGF. Furthermore, conditioned media from DRZ-V-treated macrophages enhanced fibroblast migration, indicating indirect pro-reparative effects mediated through macrophage modulation. Mechanistically, these effects were associated with reduced TIRAP phosphorylation and attenuation of NF-κB activation.
conclusionDRZ-V promotes wound repair by modulating macrophage-mediated inflammatory responses through inhibition of TIRAP-NF-κB signaling, highlighting its therapeutic potential for inflammatory and impaired wound healing conditions.
Indexed as
Identifiers
42310187What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.